Robert W. Baird Increases DexCom (NASDAQ:DXCM) Price Target to $240.00

DexCom (NASDAQ:DXCM) had its price objective raised by Robert W. Baird from $195.00 to $240.00 in a research note issued to investors on Thursday morning, The Fly reports. They currently have an outperform rating on the medical device company’s stock.

A number of other brokerages also recently commented on DXCM. BMO Capital Markets upped their price objective on DexCom from $180.00 to $190.00 and gave the stock an outperform rating in a research note on Tuesday, September 3rd. Stifel Nicolaus began coverage on DexCom in a research note on Tuesday, October 22nd. They set a buy rating and a $190.00 price objective for the company. UBS Group upped their price objective on DexCom from $140.00 to $160.00 and gave the stock a neutral rating in a research note on Thursday, August 1st. Bank of America upped their price objective on DexCom from $162.00 to $185.00 and gave the stock a buy rating in a research note on Thursday, August 1st. Finally, Raymond James upped their price objective on DexCom from $150.00 to $172.00 and gave the stock an outperform rating in a research note on Thursday, August 1st. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. DexCom presently has an average rating of Buy and an average price target of $190.67.

DexCom stock traded up $3.38 during midday trading on Thursday, hitting $198.08. 2,580,200 shares of the company were exchanged, compared to its average volume of 1,138,483. DexCom has a fifty-two week low of $105.05 and a fifty-two week high of $200.80. The company has a debt-to-equity ratio of 1.56, a current ratio of 6.05 and a quick ratio of 5.64. The company has a market cap of $14.00 billion, a PE ratio of 660.27 and a beta of 0.64. The company’s fifty day moving average price is $155.57 and its 200-day moving average price is $146.29.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.45. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The business had revenue of $396.30 million during the quarter, compared to the consensus estimate of $348.99 million. During the same period in the previous year, the business earned $0.17 EPS. The business’s quarterly revenue was up 48.6% on a year-over-year basis. On average, analysts expect that DexCom will post 0.94 EPS for the current fiscal year.

In other news, Director Nicholas Augustinos sold 1,208 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $185.29, for a total value of $223,830.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 10,000 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $156.12, for a total value of $1,561,200.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,222 shares of company stock valued at $16,407,406. 1.80% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Gradient Investments LLC bought a new position in shares of DexCom in the second quarter worth $25,000. Virtus ETF Advisers LLC bought a new position in shares of DexCom in the second quarter worth $29,000. Steward Partners Investment Advisory LLC bought a new position in shares of DexCom in the second quarter worth $31,000. CSat Investment Advisory L.P. bought a new position in shares of DexCom in the second quarter worth $31,000. Finally, Wealthcare Advisory Partners LLC acquired a new stake in shares of DexCom in the second quarter valued at $37,000. 96.19% of the stock is owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: Why do analysts give a neutral rating?

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.